A study to characterize the safety, efficacy, pharmacokinetics of subcutaneous administration of Etentamig (ABBV-383) in patients with relapsed or refractory Multiple Myeloma

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-507901-32-00

Acronym

M23-001

Enrollment

Registered

2024-05-13

Start date

2024-06-28

Completion date

Unknown

Last updated

2025-10-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed or Refractory Multiple Myeloma (R/R MM)

None listed

Sex/Gender

All

Age

18 Years to No maximum

France, Germany

None listed

Source: EU CTIS · Data processed: Feb 4, 2026